Analysts think FGEN stock price could increase by 1946%
Dec 25, 2024, 12:26 PM
1.52%
What does FGEN do
FibroGen, headquartered in San Francisco, focuses on developing novel therapeutics for cancer and anemia, with key products including Pamrevlumab and Roxadustat. The company went public on November 14, 2014, and employs 486 staff.
3 analysts think FGEN stock price will increase by 1945.73%. The current median analyst target is $10.20 compared to a current stock price of $0.50. The lowest analysts target is $10.10 and the highest analyst target is $10.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
